Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-label, Study of Voruciclib in Subjects With Relapsed and/or Refractory B Cell Malignancies or AML After Failure of Prior Standard Therapies and Voruciclib in Combination With Venetoclax in Subjects With Relapsed/Refractory AML

NCT03547115 is registered in ClinicalTrials.gov with MEI Pharma, Inc. as lead sponsor.

NCT NCT03547115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03547115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-label, Study of Voruciclib in Subjects With Relapsed and/or Refractory B Cell Malignancies or AML After Failure of Prior Standard Therapies and Voruciclib in Combination With Venetoclax in Subjects With Relapsed/Refractory AML
Lead sponsor
MEI Pharma, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2018
Completion date
July 24, 2024
Enrollment
84 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), chronic lymphocytic leukemia (cll), diffuse large b-cell lymphoma (dlbcl), follicular lymphoma (fl), mantle cell lymphoma (mcl), marginal zone lymphoma (mzl), small lymphocytic lymphoma (sll)